Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

Y0000271

Oxaliplatin

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

[SP-4-2-(1R-trans)]-(1,2-Cyclohexanediamine-N,N′)[ethanedioata(2--)-O,O’]platinum

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización

Seleccione un Tamaño

250 MG
MXP 3,721.00

MXP 3,721.00

Check Cart for Availability
Solicitar un pedido a granel
Todas las fotos(1)

Seleccione un Tamaño

Cambiar Vistas
250 MG
MXP 3,721.00

About This Item

Fórmula empírica (notación de Hill):
C8H14N2O4Pt
Número de CAS:
61825-94-3
Peso molecular:
397.29
Número MDL:
MFCD00866327
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329830895
NACRES:
NA.24

MXP 3,721.00

Check Cart for Availability
Solicitar un pedido a granel

grado

pharmaceutical primary standard

familia API

oxaliplatin

fabricante / nombre comercial

EDQM

aplicaciones

pharmaceutical (small molecule)

Formato

neat

temp. de almacenamiento

2-8°C

cadena SMILES

O=C1O[Pt]OC1=O.N[C@@H]2CCCC[C@H]2N

InChI

1S/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1

Clave InChI

ZROHGHOFXNOHSO-BNTLRKBRSA-L

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Oxaliplatin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

Y0000275

Dichlorodiaminocyclohexaneplatinum, European Pharmacopoeia (EP) Reference Standard

Y0000273

Oxaliplatin impurity C, European Pharmacopoeia (EP) Reference Standard

Y0000274

Oxaliplatin impurity D, European Pharmacopoeia (EP) Reference Standard

Y0000272

Oxaliplatin impurity B, European Pharmacopoeia (EP) Reference Standard

1481204

Oxaliplatin, United States Pharmacopeia (USP) Reference Standard

1481226

Oxaliplatin Related Compound B, United States Pharmacopeia (USP) Reference Standard

1481215

Oxaliplatin Related Compound A, United States Pharmacopeia (USP) Reference Standard

1481237

Oxaliplatin Related Compound C, United States Pharmacopeia (USP) Reference Standard

1481248

Oxaliplatin Related Compound D, United States Pharmacopeia (USP) Reference Standard

1481306

Oxaliplatin System Suitability, United States Pharmacopeia (USP) Reference Standard

1481260

Oxaliplatin Related Compound F, United States Pharmacopeia (USP) Reference Standard

PHR2545

Oxaliplatin Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogramas

Health hazardCorrosion
GHS08,GHS05

Palabra de señalización

Danger

Clasificaciones de peligro

Carc. 2 - Eye Dam. 1 - Lact. - Muta. 2 - Repr. 1B - Resp. Sens. 1B - Skin Sens. 1 - STOT RE 1

Código de clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Bernard Nordlinger et al.
The Lancet. Oncology, 14(12), 1208-1215 (2013-10-15)
Previous results of the EORTC intergroup trial 40983 showed that perioperative chemotherapy with FOLFOX4 (folinic acid, fluorouracil, and oxaliplatin) increases progression-free survival (PFS) compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer. Here we present
Noriho Iida et al.
Science (New York, N.Y.), 342(6161), 967-970 (2013-11-23)
The gut microbiota influences both local and systemic inflammation. Inflammation contributes to development, progression, and treatment of cancer, but it remains unclear whether commensal bacteria affect inflammation in the sterile tumor microenvironment. Here, we show that disruption of the microbiota
Catia Moutinho et al.
Journal of the National Cancer Institute, 106(1), djt322-djt322 (2013-11-26)
A major problem in cancer chemotherapy is the existence of primary resistance and/or the acquisition of secondary resistance. Many cellular defects contribute to chemoresistance, but epigenetic changes can also be a cause. A DNA methylation microarray was used to identify
Kristina Jansson et al.
Environmental and molecular mutagenesis, 54(5), 327-337 (2013-05-17)
The highly conserved DNA glycosylase MutY is implicated in repair of oxidative DNA damage, in particular in removing adenines misincorporated opposite 7,8-dihydro-8-oxoguanine (8-oxo-G). The MutY homologues (MutYH) physically associate with proteins implicated in replication, DNA repair, and checkpoint signaling, specifically
Roser Velasco et al.
Journal of neurology, neurosurgery, and psychiatry, 85(4), 392-398 (2013-07-03)
Peripheral neuropathy ranks among the most common dose-limiting and disabling side-effect of oxaliplatin (OXA)-based chemotherapy. The aim of this prospective, multicentre study was to define early clinical and neurophysiological markers that may help to identify patients at risk of developing
Ver todos los artículos relacionados

Questions

  1. Hello, Could you tell me the quantity of Y0000271 Oxaliplatin European Pharmacopoeia (EP) reference standard.  Bonjour, Pourriez-vous m'informer de la quantité de Y0000271 Oxaliplatine Standard de référence de la Pharmacopée européenne (EP). 

    1 answer

    1. This is a product of the European Pharmacopoeia. Each vial contains 250 mg of Oxaliplatin.

      Please see the link below to visit the European Pharmacopeia website for more information and to download the product leaflet: https://crs.edqm.eu/db/4DCGI/View=Y0000271

      Helpful?

Reviews

No rating value

Active Filters

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico